AAOS invests in biologics R&D, seeks to develop knowledge for musculoskeletal care

Alan Condon -   Print  |

The American Academy of Orthopaedic Surgeons is investing in research and development for biologics in a five-year initiative announced on Nov. 20.

AAOS will focus on generating evidence-based, unbiased information and educational content to guide orthopedic surgeons and their patients in the field.

It plans to identify and build on the biologic gaps in musculoskeletal treatment and tackle the issue of misinformation, which stems from direct-to-consumer marketing of biologic treatments.

The organization will conduct literature reviews and symposia discussions as well as develop white paper and consensus statements to grow biologic knowledge and its application to musculoskeletal care.

More articles on biologics:
Orthofix's M6-C cervical disc in 2019: 7 key developments
Dr. Robert Brady: How the 2020 CMS final rule will affect the spine field
How OrthoNY is trying to solve its recruiting problem

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers